[go: up one dir, main page]

CL2012003729A1 - Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. - Google Patents

Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.

Info

Publication number
CL2012003729A1
CL2012003729A1 CL2012003729A CL2012003729A CL2012003729A1 CL 2012003729 A1 CL2012003729 A1 CL 2012003729A1 CL 2012003729 A CL2012003729 A CL 2012003729A CL 2012003729 A CL2012003729 A CL 2012003729A CL 2012003729 A1 CL2012003729 A1 CL 2012003729A1
Authority
CL
Chile
Prior art keywords
benzimidazol
quinolin
piperazin
disintegrant
fluoro
Prior art date
Application number
CL2012003729A
Other languages
English (en)
Inventor
Jeewan Thakur
Zhihui Qiu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012003729A1 publication Critical patent/CL2012003729A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o más rellenos, un desintegrante y un lubricante; proceso de preparación de la composición.
CL2012003729A 2010-06-30 2012-12-28 Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion. CL2012003729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10168028 2010-06-30

Publications (1)

Publication Number Publication Date
CL2012003729A1 true CL2012003729A1 (es) 2013-04-12

Family

ID=42751565

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003729A CL2012003729A1 (es) 2010-06-30 2012-12-28 Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.

Country Status (38)

Country Link
US (1) US9545402B2 (es)
EP (2) EP3446686A1 (es)
JP (1) JP6043281B2 (es)
KR (2) KR20130091319A (es)
CN (2) CN103068373A (es)
AR (1) AR081776A1 (es)
AU (1) AU2011273519B2 (es)
BR (1) BR112012033479A8 (es)
CA (1) CA2801826C (es)
CL (1) CL2012003729A1 (es)
CO (1) CO6650354A2 (es)
CR (1) CR20120623A (es)
CU (1) CU20120177A7 (es)
DK (1) DK2588086T3 (es)
DO (1) DOP2012000324A (es)
EA (1) EA026244B1 (es)
EC (1) ECSP13012411A (es)
ES (1) ES2701161T3 (es)
GE (1) GEP20146049B (es)
GT (1) GT201200348A (es)
HU (1) HUE042355T2 (es)
IL (1) IL223799A (es)
MA (1) MA34387B1 (es)
MX (1) MX345404B (es)
MY (2) MY163369A (es)
NI (1) NI201200189A (es)
NZ (1) NZ604055A (es)
PE (1) PE20130481A1 (es)
PH (1) PH12012502519A1 (es)
PL (1) PL2588086T3 (es)
PT (1) PT2588086T (es)
SG (1) SG186182A1 (es)
TN (1) TN2012000574A1 (es)
TR (1) TR201818761T4 (es)
TW (1) TWI583384B (es)
UA (1) UA109659C2 (es)
UY (1) UY33472A (es)
WO (1) WO2012001074A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
BR112014017985A8 (pt) 2012-01-31 2017-07-11 Novartis Ag Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
KR20150036014A (ko) 2012-07-11 2015-04-07 노파르티스 아게 위장 기질 종양을 치료하는 방법
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
SI2968529T1 (sl) 2013-03-14 2021-03-31 Aimmune Therapeutics, Inc. Izdelava arašidovih formulacij arašida za ustno desenzibilizacijo
CA2930552C (en) 2013-11-15 2022-12-13 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2015187736A1 (en) * 2014-06-02 2015-12-10 Allergen Research Corporation Placebo formulations and uses thereof
CA2970010A1 (en) 2014-12-09 2016-06-16 Karen Havenstrite Medical device coating with a biocompatible layer
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
BR112017024337A2 (pt) * 2015-05-22 2018-07-31 Novartis Ag composições farmacêuticas
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2022026851A1 (en) * 2020-07-31 2022-02-03 The Scripps Research Institute Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna
WO2025067365A1 (zh) * 2023-09-27 2025-04-03 南京迈诺威医药科技有限公司 含有别孕烷醇酮衍生物的药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP1904480A2 (en) * 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
JP2009517481A (ja) * 2005-11-29 2009-04-30 ノバルティス アクチエンゲゼルシャフト キノリノンの製剤
CN101316593B (zh) * 2005-11-29 2012-05-02 诺瓦提斯公司 喹啉酮类的制剂
AU2008226582B2 (en) 2007-03-09 2011-07-21 Novartis Ag Treatment of melanoma
CA2696807C (en) 2007-11-08 2017-11-28 Ambit Biosciences Corp. Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
BR112012026285A2 (pt) 2010-04-16 2016-07-12 Novartis Ag combinação de compostos orgânicos

Also Published As

Publication number Publication date
MY163369A (en) 2017-09-15
CR20120623A (es) 2013-02-11
IL223799A (en) 2017-04-30
ES2701161T3 (es) 2019-02-21
NZ604055A (en) 2015-02-27
US20130090344A1 (en) 2013-04-11
CU20120177A7 (es) 2013-04-19
NI201200189A (es) 2013-12-17
CO6650354A2 (es) 2013-04-15
WO2012001074A3 (en) 2012-03-22
ECSP13012411A (es) 2013-03-28
MY177741A (en) 2020-09-23
PL2588086T3 (pl) 2019-04-30
US9545402B2 (en) 2017-01-17
TR201818761T4 (tr) 2019-01-21
AR081776A1 (es) 2012-10-17
CN106943355A (zh) 2017-07-14
EP2588086B1 (en) 2018-09-12
PT2588086T (pt) 2018-12-18
TN2012000574A1 (en) 2014-04-01
MX2012015091A (es) 2013-02-12
WO2012001074A2 (en) 2012-01-05
KR20170139170A (ko) 2017-12-18
DOP2012000324A (es) 2013-02-28
BR112012033479A8 (pt) 2017-10-31
JP6043281B2 (ja) 2016-12-14
AU2011273519B2 (en) 2014-05-15
MA34387B1 (fr) 2013-07-03
UA109659C2 (xx) 2015-09-25
PE20130481A1 (es) 2013-05-01
EA201291410A1 (ru) 2013-05-30
EP2588086A2 (en) 2013-05-08
PH12012502519A1 (en) 2021-06-23
EA026244B1 (ru) 2017-03-31
CA2801826A1 (en) 2012-01-05
TWI583384B (zh) 2017-05-21
GT201200348A (es) 2014-03-14
AU2011273519A1 (en) 2013-01-31
JP2013530196A (ja) 2013-07-25
SG186182A1 (en) 2013-01-30
TW201206903A (en) 2012-02-16
HUE042355T2 (hu) 2019-06-28
MX345404B (es) 2017-01-30
DK2588086T3 (en) 2019-01-07
CN106943355B (zh) 2020-09-01
BR112012033479A2 (pt) 2016-11-29
KR20130091319A (ko) 2013-08-16
KR101840182B1 (ko) 2018-03-19
CA2801826C (en) 2018-04-10
EP3446686A1 (en) 2019-02-27
CN103068373A (zh) 2013-04-24
UY33472A (es) 2012-01-31
GEP20146049B (en) 2014-02-25

Similar Documents

Publication Publication Date Title
CL2012003729A1 (es) Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.
AR114143A2 (es) Formulaciones de comprimidos revestidos
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
GB2514951C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
LT3111926T (lt) Kompozicijos, būdai ir sistemos dviejų arba kelių veikliųjų agentų respiraciniam pateikimui
TW201711676A (en) Ferric citrate dosage forms
LT2493474T (lt) Būdai ir kompozicijos prolonguotam vaistų įvedimui
SV2010003744A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
BR112014025041B8 (pt) Composição farmacêutica
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
DOP2015000089A (es) Composición de difenidol de liberación prolongada
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
EP2672985A4 (en) CITRATE-FREE PHARMACEUTICAL COMPOSITIONS WITH ANAKINRA
UY34081A (es) Composición farmacéutica que comprende drotaverina
HK1179879A (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
CL2009000790S1 (es) Desodorizador de aire.
MX2012014498A (es) Composicion farmaceutica de rosuvastatina.
UY34865A (es) Una composición acuosa que comprende dicamba y un agente de control de la deriva
TH1501001478A (th) องค์ประกอบทางเภสัชกรรมสำหรับการให้ทางปากซึ่งมีการละลาย และ/หรือ การดูดซึมดีขึ้น
ES1074770U8 (es) Maniquí con fines médicos para práctica de la intubación oral en pacientes.